NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/21/2026 10:30
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,232.51 mln
Float388 mln
Earnings Date08/06/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.71
Likely reliable
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.07
Debt-free
ROE
-49.30
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Iovance Biotherapeutics is a California-based company that creates cancer treatments by extracting and multiplying a patient's own immune cells to fight tumors. Its lead product, Amtagvi, is approved for adults with advanced melanoma that has not responded to prior treatment, while Proleukin serves patients with melanoma and kidney cancer. The company has a broad pipeline targeting several other cancers, including cervical, lung, and head and neck cancers, and works alongside major research institutions and pharmaceutical partners to advance its therapies.